Neurocrine Biosciences
NBIX
#1451
Rank
A$18.49 B
Marketcap
$182.71
Share price
-3.89%
Change (1 day)
5.68%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.98

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.03. In 2022 the company made an earnings per share (EPS) of $2.49 an increase over its 2021 EPS that were of $1.47.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.9819.57%
2022$2.4969.47%
2021$1.47-78.21%
2020$6.75990%
2019$0.6281.82%
2018$0.34-113.5%
2017-$2.520.62%
2016-$2.5157.28%
2015-$1.5925.61%
2014-$1.2718.84%
2013-$1.07-1085.71%
2012$0.11-89.71%
2011$1.05-500%
2010-$0.26-86.92%
2009-$2.01-43.48%
2008-$3.56-57.8%
2007-$8.4392.58%
2006-$4.38371.67%
2005-$0.93-52.76%
2004-$1.9636.56%
2003-$1.44-70%
2002-$4.80118.31%
2001-$2.208.4%
2000-$2.0348.86%
1999-$1.36-20%
1998-$1.70-479.31%
1997$0.45

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.23 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.85-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.58-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$8.40 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.69 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.88-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.73-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.69-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA